nereby trendy that this correspondence is being facsimile transmitted to the Patent and Trademark Office at the Office of Paritions, Fax. No. 5 on the gate shown below

Docket No.: SCHERING 3.0-121 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patient Application of:

Anil Saksena

Application No.: 09/909,012

Group Art Unit: 1653

Filed: July 19, 2001

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE

PROTEASE INHIBITORS OF HEPATITIS

C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR \$ 1.97 (C)

Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our deposit account No. 12-1095.

Dated: April 12, 2005

Respectfully submitted,

Harvey L. Cohen

Registration No.: 28,365 LERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP 600 South Avenue West Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-4531

556113

Patent and Trademark Office at the Office of Pelitions Fax, No. 57, 73-0025

On the date shown below

Dated April 12, 2005. Signature: Harvey L. Opien.

Docket No.: SCHERING 3.0-121 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Anil Saksena

Application No.: 09/909,012

Group Art Unit: 1653

Filed: July 19, 2001

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE PROTEASE

INHIBITORS OF HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed. Submission of 'the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is nereby authorized to charge the same to our Deposit Account No. 12:1095.

Pated: April 12, 2005

Respectfully submitted,

Harvey L. Cohen

Registration No.: 28,365

LERNER, DAVID, LITTENBERG, KRUMHOLZ

& MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

1 [1-4-5

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Paleni and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1955, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/B/FTCI				Complete If Known		
		-		Application Number	09/909,012	
ı	NFORMATION	N DI	SCLOSURE	Filing Date	July 19, 2001	
5	STATEMENT BY APPLICANT			First Named Inventor	Anii Saksena	
			• • • • •	Art Unit	1653	
	(Use as many sncets as necessary)			Examiner Name	R. B. Mondesi	
Sheet	1.	of	1	Attorney Docket Number	SCHERING 3.0-122 CIP	

U.S. PATENT DOCUMENTS						
Eraminer Cite	Document Number Number-Kind Chae ² (# known)	Publication Date	Nome of Patentee or Applicant of Giled Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cité No	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Palentee or	Pages, Columne, Linea, Where Relevant Passages or Relevant Figures Appear	
		Caunity Code ³ -Number ⁴ -Kind Code ⁴ (if known)		Applicant of Cited Document		
	₿A	JP-4-001140-A	01-06-1992	Microbial Chem		

'6 KAMINAR Initial II releiance considered, whether or not clastion is in conformance with MPEP 909. Draw this through citation if not in conformance and not considered for use copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of CLAPTO Patient Documents at www.spip.gov/ or MPEP 901.04. Beniar Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Joseph Documents are indication of the year of the reign of the Emperor must precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language. fransiation is altached

	NON PATENT LITERATURE DOCUMENTS					
Examiner initials	Cite No.	Include name of the author (in CAPITAL LETTERS), this of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, City and/or country where published.	T²			
	CA	Patel et al., Activated Ketone Based Inhibitors of Human Renin, Journal of Medicinal IChemistry, 1993, Volume 36, Number 17, August 20, 1993, pages 2431-2447				
	СВ	Asano et al., Novel Retrovirus Protease Inhibitors, RPI-856 A, B, C and D, The Journal of Antiopiotics, Volume 47, No. 5, pages 557-565 (1994)				
	CC	Suto et al., Peptide Inhibitors of IKB Protease: Modification of the C-Termini of Z-LLF-CHO, Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 24, pp. 2925-2930 (1996)				

^{15.04}MINER fortial if reference considered, whether or not cliation talin conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

556100

[&]quot;Applicant's unique cliation sesignation number (optional). "Applicant is to place a check mark here if English language Translation is attached.